SWOG 0816: A Phase II Trial of Response Adapted Therapy of Stage III-lV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging
||Michael Grossbard, MD
| Time frame of study:
|Location of Study:
Beth Israel Medical Center
St.Luke's-Roosevelt Hospital Center
Continuum Cancer Research Program
This is an investigational study designed to find out if it is possible to use early periodic Positron Emission Tomography (PET scans) to identify those subjects who are not responding to a standard chemotherapy called "ABVD" (the drugs doxorubicin, bleomycin, vinblastine and dacarbazine). ABVD is standard and the most common chemotherapy regimen for newly diagnosed all stages of Hodgkin’s disease. This approach would allow an earlier switch to a more intensive chemotherapy regimen called "BEACOPP" (the drugs bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone), which is not standard of care. The goal of this study is to find out if the experimental treatment of switching from ABVD to BEACOPP using periodic PET scanning will improve the chances that subjects’ Hodgkin lymphoma will be cured.
- All subjects must have previously untreated Stage III or IV classical Hodgkin lymphoma.
- Subjects must be between 18 and 60 years of age.
- Subjects must not have received prior chemotherapy, radiation, or antibody therapy for lymphoma.
- HIV-positive subjects must not have multi-drug resistant HIV infection.
- Subjects must not have significant lung disease with abnormal lung function.
- Subjects must not have had prior solid organ transplantation.
Please call for more information